Pinnbrook Capital Management LP Increases Stock Position in Natera, Inc. $NTRA

Key Points

• Pinnbrook Capital Management LP increased its stake in Natera by 16.6% in the fourth quarter, adding 5,968 shares to reach 41,882 shares valued at about $9.6 million.
• Natera reported stronger-than-expected quarterly results, posting $0.35 EPS versus estimates for a loss and generating $665.5 million in revenue, ahead of analyst forecasts.
• Analyst sentiment remains generally positive, with an average rating of “Moderate Buy” and an average price target of $256.60, though some insiders recently sold shares under pre-arranged trading plans.

Pinnbrook Capital Management LP boosted its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 16.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 41,882 shares of the medical research company's stock after purchasing an additional 5,968 shares during the quarter. Natera comprises approximately 1.3% of Pinnbrook Capital Management LP's holdings, making the stock its 22nd largest holding. Pinnbrook Capital Management LP's holdings in Natera were worth $9,595,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of the stock. Horizon Investments LLC lifted its stake in Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company's stock worth $56,000 after purchasing an additional 44 shares in the last quarter. Sound Income Strategies LLC increased its holdings in shares of Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company's stock worth $62,000 after buying an additional 45 shares during the last quarter. Savvy Advisors Inc. increased its holdings in shares of Natera by 3.1% in the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company's stock worth $353,000 after buying an additional 46 shares during the last quarter. Siemens Fonds Invest GmbH increased its holdings in shares of Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company's stock worth $290,000 after buying an additional 54 shares during the last quarter. Finally, First Horizon Corp increased its holdings in shares of Natera by 7.3% in the 4th quarter. First Horizon Corp now owns 931 shares of the medical research company's stock worth $213,000 after buying an additional 63 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Trading Down 0.6%

Shares of NASDAQ:NTRA opened at $203.69 on Friday. The company has a market capitalization of $29.17 billion, a price-to-earnings ratio of -124.96 and a beta of 1.57. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $256.36. The firm's 50-day moving average is $200.78 and its 200 day moving average is $215.41.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.81. The business had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative net margin of 9.05% and a negative return on equity of 14.74%. During the same period in the prior year, the firm earned ($0.41) EPS. As a group, equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on NTRA shares. William Blair started coverage on shares of Natera in a report on Tuesday, April 14th. They issued an "outperform" rating on the stock. Evercore restated an "outperform" rating and issued a $270.00 target price on shares of Natera in a report on Friday, May 8th. Wells Fargo & Company boosted their target price on shares of Natera from $215.00 to $220.00 and gave the stock an "equal weight" rating in a report on Friday, May 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Natera in a report on Tuesday, April 21st. Finally, Robert W. Baird set a $265.00 target price on shares of Natera in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $256.60.

Insider Activity at Natera

In other Natera news, insider Solomon Moshkevich sold 3,405 shares of the company's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $203.69, for a total value of $693,564.45. Following the transaction, the insider directly owned 142,295 shares in the company, valued at $28,984,068.55. This represents a 2.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 1,688 shares of the company's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $204.10, for a total transaction of $344,520.80. Following the completion of the transaction, the insider owned 187,511 shares in the company, valued at $38,270,995.10. This represents a 0.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 38,266 shares of company stock valued at $7,747,808 over the last 90 days. 5.63% of the stock is currently owned by insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.